J&J Sags in Medical Device, Still Plans to Launch 30 Products by 2016
Despite Johnson & Johnson’s sluggish start to the year in its medical device business, the company is holding to its strategy to launch 30 new products by next year. Globally, medical device sales dropped 4.6% to $6.3 billion, with U.S. sales declining 6.1%.
During yesterday’s earnings call, Dominic Caruso, VP, finance and CFO at Johnson & Johnson referred to the company’s collaboration agreement with Google Life Sciences to develop a surgical robotics program, which was announced in March, as a step to “accelerate growth through innovation.” Caruso remained positive about the company’s direction in the medical device space, but acknowledged the negatives—pricing in its vision care business, which he called a “drag” year-over-year, and pricing headwinds in its diabetes business.
“We’re very optimistic about the fact that the medical device business will return to grow, especially once we lap some of these comparisons,” said Caruso. “We see the benefits of the new products that we’re launching.” Some of this optimism comes from shedding the Cordis business, which the company sees as a commodity business at this point, and holding on to a more fruitful space in cardiovascular devices with Biosense Webster, which offers products that diagnose and treat cardiac arrhythmias.
Related Articles
-
The UK MHRA has published “Software and Artificial Intelligence as a Medical Device.” The guidance document assembles previous guidances and regulatory requirements for SaMD and AIaMD devices seeking commercialization in the UK market.
-
“Addressing unmet needs across pediatric populations is critical to advancing children’s health, and we are delighted to once again work with pioneering companies that seek to bridge this care gap."
-
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify…
-
More and more, the quality of real-world evidence (RWE)—gathered from remote patient monitoring data, product and disease registry data, and patient feedback—determines whether a medical device is approved and, in some instances, for how long. Yet some medical device manufacturers…
About The Author
MedTech Intelligence Staff
The MedTech Intelligence staff consists of freelance journalists and industry contributing writers with decades of experience in covering medical device issues under the categories of business, market trends, product development, quality, regulatory, and operations.
You can contact our writing staff via our Contact Page.